COGNIZANT TECHNOLOGY SOLUTIONS CORP Q1 FY2025 earnings call

First quarter revenue was $5.1 billion, up 8.2% year-over-year in constant currency, driven by Belcan acquisition and organic growth in Health Sciences and Financial Services. Adjusted operating margin was 15.5%, up 40 basis points year-over-year, on track for 20-40 basis points expansion in 2025. There were ~1,400 early GenAI engagements, with key vectors including AI-led productivity, industrializing AI, and agentification. Strategic imperatives include amplifying talent (upskilling workforce, 14-acre learning center in Chennai), scaling innovation (BlueBolt, awards), and accelerating growth (AI and embedded engineering, GCC strategy). Client wins include partnerships with Boehringer Ingelheim, OMRON, Manulife John Hancock Retirement, and a new GCC with Citizens Financial.

Health Sciences led revenue growth with over 11% year-over-year constant currency growth, broad-based across payer, provider, and life sciences. Financial Services grew 6.5% year-over-year constant currency for the third straight quarter, with healthy discretionary spending in cloud and data modernization. Products and Resources' Q1 growth was driven by Belcan, but organically weak due to discretionary spending pressure. Communications, Media and Technology was roughly flat sequentially but had a healthy pipeline for GenAI-led deals. North America grew 10% year-over-year constant currency, Europe 3% year-over-year, and the rest of the world ~7% year-over-year in constant currency.

For Q2 2025, revenue is expected to grow 5%-6.5% year-over-year in constant currency. Full-year 2025 guidance includes revenue growth of 3.5%-6% in constant currency, adjusted operating margin of 15.5%-15.7% (20-40 basis points expansion), EPS of $4.98-$5.14 (5%-8% growth), free cash flow >90% of net income, and ~$1.7 billion return to shareholders via repurchases and dividends.

Macro environment changes in early April with continued uncertainty affecting client decision-making and discretionary spending. Products and Resources segment affected by discretionary spending pressure and geopolitical/tariff policies.

Q: Shift in bookings quality and pricing/margin on large deals?

A: Ravi and Jatin discussed winning deals based on solution strength, execution, and AI productivity; large deals TCV higher than last year, pipeline of mega deals.

Q: April slowdown isolation and Belcan exposure?

A: Isolation in certain segments like health and products/resources; Belcan works on engineering, low exposure to government contracts.

Q: Organic growth acceleration and labor market?

A: Organic growth from Health Sciences and Financial Services; attrition stable, fulfillment good.

Q: Backlog coverage and gross margin trends?

A: Book-to-bill 1.3 trailing 12 months; margin improvement from operating expenses, not gross margin primarily.

Q: Sustainability of winner’s circle and pricing environment?

A: Sustainability through consistency, broad portfolio; pricing led by solution strength and AI capabilities.